Sanofi-aventis

Kinga Boér

Lajos T Nagy

Zoltán Szlávik

Endre Mikus

Sándor Bátori

Katalin Urbán-Szabó

Zoltán Kapui

László Balázs

Mária Balogh

Imre Bata

Katalin Gerber

Tibor Szabó

Péter Arányi

Géza Timári

Geza Tímári

Zsuzsanna Szamosvölgyi

Edit Susán

T Nagy Lajos

Judit Vargáné Szeredi

Peter Arányi

Olivier Finance

Gábor Szeleczky

Katalin Urbán Szabó

Michel Finet

The present invention relates to adenosine Areceptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containings them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and (III) and to the preparation thereof. 

Imidazoquinoline derivatives and their use as adenosine A3 ligands

Compounds of general formula (I), wherein Rand Rstand for hydrogen atom or form together an 1,3-butadienyl group, optionally substituted by a methylenedioxy group or one or more straight or branched Calkyl group, straight or branched Calkoxy group, hydroxy group or halogen atom; are strong adenosine Areceptor ligands preferably antagonists.

Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands

Growing community of inventors

Budapest, Hungary

Kinga Boér